Y. Lis

1.3k citations

16 papers · 991 indexed · 1 hit paper · h-index 12

Impact in

Pharmacology top 5%
- Pharmacogenetics and Drug Metabolism
Pharmaceutical Science top 5%
- Drug Solubulity and Delivery Systems

Papers in ⓘ

Family Practice 1
Toxicology 1
- Pharmacovigilance and Adverse Drug Reactions 1

Co-authors: SR Walker (2 shared papers)Dennis W. Raisch (2 shared papers)Jeff J. Guo (2 shared papers)John Doyle (1 shared paper)Boyang Bian (1 shared paper)Roderick A.F. MacLeod (1 shared paper)Wilhelm G. Dirks (1 shared paper)E. Becker (1 shared paper)
Journals: Value in Health (3 papers)Pharmacoepidemiology and Drug Safety (2 papers)British Journal of Clinical Pharmacology (2 papers)Biochemical Journal (2 papers)Current Medical Research and Opinion (1 paper)
Partner nations: United Kingdom United States Canada

In The Last Decade

Y. Lis

16 papers receiving 919 citations

Hit Papers

align trajectories log scale

Pharmaceutical innovation by the seven UK‐owned pharmaceutical companies (1964‐1985). 1988 · 338 citations

Peers

Countries citing papers authored by Y. Lis

Since Specialization

Citations

This map shows the geographic impact of Y. Lis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Y. Lis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Y. Lis more than expected).

Fields of papers citing papers by Y. Lis

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Y. Lis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Y. Lis. The network helps show where Y. Lis may publish in the future.

Co-authors

The 25 scholars most cited alongside Y. Lis, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Y. Lis Line = papers co-authored together Y. Lis links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

#	Work
1	Pharmaceutical innovation by the seven UK‐owned pharmaceutical companies (1964‐1985). British Journal of Clinical Pharmacology ·RA Prentis, Y. Lis, SR Walker Hit paper breakdown →	1988	338
2	A Review of Quantitative Risk–Benefit Methodologies for Assessing Drug Safety and Efficacy—Report of the ISPOR Risk–Benefit Management Working Group Value in Health ·Jeff J. Guo, Swapnil Pandey, John Doyle, Boyang Bian, Y. Lis, Dennis W. Raisch	2010	150
3	The VAMP research multi-purpose database in the U.K. Journal of Clinical Epidemiology ·Y. Lis	1995	109
4	Expression and functional analysis of the anaplastic lymphoma kinase (ALK) gene in tumor cell lines International Journal of Cancer ·Wilhelm G. Dirks, Silke Fähnrich, Y. Lis, E. Becker, Roderick A.F. MacLeod, Hans G. Drexler	2002	103
5	Biochemical characterization of individual normal, floppy and rheumatic human mitral valves Biochemical Journal ·Y. Lis, Mary C. Burleigh, D J Parker, Anne H. Child, Jane Hogg, Michael J. Davies	1987	62
6	The impact of dosing frequency on compliance and persistence with bisphosphonates among postmenopausal women in the UK: evidence from three databases Current Medical Research and Opinion ·E. Brankin, Mel Walker, Niall Lynch, Terry Aspray, Y. Lis, Warren Cowell	2006	54
7	A preliminary double-blind study of intravenous nitroglycerin in acute myocardial infarction Intensive Care Medicine ·Y. Lis, Deborah H. Bennett, George H. Lambert, D. Robson	1984	49
8	The iron content of human liver and spleen isoferritins correlates with their isoelectric point and subunit composition Biochemical and Biophysical Research Communications ·Adrian Bomford, Marc Berger, Y. Lis, Roger Williams	1978	33
9	Comparisons of Food and Drug Administration and European Medicines Agency Risk Management Implementation for Recent Pharmaceutical Approvals: Report of the International Society for Pharmacoeconomics and Outcomes Research Risk Benefit Management Working Group Value in Health ·Y. Lis, Melissa Roberts, Shital Kamble, Jeff J. Guo, Dennis W. Raisch	2012	28
10	Variation in the distribution of two human heart ferritin species. Isoferritin profile and subunit composition in normal and iron-overloaded subjects Biochemical Journal ·Adrian Bomford, Y. Lis, I G McFarlane, Roger Williams	1977	25
11	A concurrent cohort study of oral contraceptive users from the VAMP research bank Pharmacoepidemiology and Drug Safety ·Y. Lis, Walter O. Spitzer, Ronald D. Mann, Joy Chukwujindu, Margaret Thorogood, Stephen Evans, Samy Suissa, Jacques LeLorier	1993	16
12	Novel medicines marketed in the UK (1960‐87). British Journal of Clinical Pharmacology ·Y. Lis, SR Walker	1989	11
13	Increased Renal Function in Patients with Acute Left Ventricular Failure: A Possible Homeostatic Mechanism Clinical Science ·Ed Bennett, N H Brooks, J R Keddie, Y. Lis, Ana Wilson	1977	8
14	Micturin (Terodiline Hydrochloride), Torsades de Pointe and other Arrhythmias — A Study using the VAMP Database Pharmacoepidemiology and Drug Safety ·Gillian C. Hall, Joy I. Chukwujindu, Jeannette Richardson, Y. Lis, R. N. Wild	1993	3
15	PCN120 The Natural History of Fludarabine-Refractory Chronic Lymphocytic Leukemia Patients Who Fail Alemtuzumab or Have Bulky Lymphadenopathy – A European Perspective Value in Health ·E De Cock, Amin Haiderali, Radoslaw Wasiak, Y. Lis, Vincent Lévy	2011	1
16	Early Administration of Oral Isorbide-5-Mononitrate (Elantan) Reduces Mortality in Patients with Acute Myocardial Infarction and Left Ventricular Failure Clinical Science ·D. Bennett, Laura Fitzgerald, Y. Lis, D. Woodings	1988	1

About Y. Lis

Y. Lis is a scholar working on Family Practice, Toxicology, Reproductive Medicine, Pharmacology and History and Philosophy of Science, having authored 16 papers that have together received 991 indexed citations. Recurring topics across this work include Pharmaceutical Economics and Policy (3 papers), Heart Failure Treatment and Management (2 papers), Hemodynamic Monitoring and Therapy (2 papers), Iron Metabolism and Disorders (2 papers), Science, Research, and Medicine (2 papers), Pharmacovigilance and Adverse Drug Reactions (1 paper), Bone health and osteoporosis research (1 paper) and Hemoglobinopathies and Related Disorders (1 paper). The work is most often cited by research in Pharmacology (134 citations), Pharmaceutical Science (82 citations), Medical Terminology (3 citations), Toxicology (30 citations) and Computational Theory and Mathematics (128 citations). Y. Lis has collaborated with scholars based in United Kingdom, United States and Canada. Frequent co-authors include SR Walker, Dennis W. Raisch, Jeff J. Guo, John Doyle, Boyang Bian, Roderick A.F. MacLeod, Wilhelm G. Dirks, E. Becker, Hans G. Drexler and Adrian Bomford. Their work appears in journals such as Value in Health, Pharmacoepidemiology and Drug Safety, British Journal of Clinical Pharmacology, Biochemical Journal and Current Medical Research and Opinion.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact